

PCT/GB 2004 / 0 0 3 4 6 5

GB04/003465

INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 27 AUG 2004

WIPO

PCT

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Stephen Handley

Dated

18 August 2004

Form 1/77

Patents Act 1977
(Rule 16)

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

13 AUG 03 15:22:00
P01/7700 0.00-0318896.8
1777

13 AUG 03 15:22:00
P01/7700 0.00-0318896.8

1. Your reference

P035070GB

2. Patent application number

(The Patent Office will fill in this part)

12 AUG 2003

0318896.8

3. Full name, address and postcode of the or of each applicant (underline all surnames)

JOHNSON & JOHNSON MEDICAL LIMITED
Erskine House
68-73 Queen Street
Edinburgh
United Kingdom
EH2 4NH

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

UK (Scotland)

6008031002

4. Title of the invention

Antimicrobial Polymers

5. Name of your agent (if you have one)

Carpmaels & Ransford

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

43 Bloomsbury Square
London
WC1A 2RA

Patents ADP number (if you know it)

83001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body

Yes

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	-
Description	31
Claim(s)	9
Abstract	1
Drawing(s)	2

10. If you are also filing any of the following, state how many against each item.

Priority documents	
Translations of priority documents	
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	
Request for preliminary examination and search (Patents Form 9/77)	1
Request for substantive examination (Patents Form 10/77)	
Any other documents (please specify)	

11. I/We request the grant of a patent on the basis of this application.

Signature

Carpmaels & Ransford

Carpmaels & Ransford

Date

11th August 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

ANTHONY C. JAMES

020-7242 8692

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

ANTIMICROBIAL POLYMERS

FIELD OF THE INVENTION

- 5 The present invention is concerned with providing antimicrobial compounds and processes for the production thereof. More particularly, the present invention provides antimicrobial polymeric materials.

BACKGROUND OF THE INVENTION

10

In developing new antimicrobial materials, it is important to discourage further antibiotic resistance. Ideally, therefore, novel antimicrobial materials will function through non-specific, non-metabolic mechanisms.

- 15 For example, polycationic (quaternary ammonium) strings developed in the laboratory of Robert Engel are reported to have antibacterial activity. See Fabian et al, Syn. Lett., 1007 (1997); Strekas et al, Arch. Biochem. and Biophys. 364, 129-131 (1999); and Cohen et al, Heteroat. Chem. II, 546-555 (2000). No suggestion has been made, however, to attach these molecules to surfaces to render the surfaces antimicrobial. Nor have there been any
20 reports regarding which of these molecules would be most effective when attached to surfaces.

- Suggestions have been made to attach other antibiotic agents, such as gentamycin and penicillin, to the surface of medical devices. See, for example, Keogh et al. U. S. Patent
25 5,476,509, Ung-Chhun et al, U. S. Patent 6,306,454, Keogh, U. S. Patent 6,033,719, Ragheb et al, U. S. Patent 6,299,604, and Guire, U. S. Patent 5,263,992. See also Kanazawa et al., Polym. Sci., Part A-I 37, 1467-1472 (1993).

- There is, clearly, a need for new materials having antimicrobial agents stably attached to
30 their surfaces. Ideally, the antimicrobial agents do not lead to resistance, and are not detached from their surfaces when the material is washed.

SUMMARY OF THE INVENTION

In accordance with a first aspect of the present invention, there is provided an antimicrobial polymeric compound having formula (1):

5



wherein:

P comprises a polymer linked to X via a carboxyl group;

10 X comprises a group $-(R-V^{m+}-R^1-R^2)_q(Y^{p-})$;

n is an integer of $1-1 \times 10^7$;

R is independently selected from divalent hydrocarbon radicals;

V comprises a positively charged moiety;

m represents an integer;

15 R^1 is independently selected from divalent hydrocarbon radicals;

R^2 is independently selected from the group consisting of -H, -SH, -F, -Cl, -Br, -I, -OR³, -HN(O)CR⁴, or -O(O)CR⁵, wherein R^3 , R^4 and R^5 are independently selected from the group consisting of -H and monovalent hydrocarbon radicals;

Y represents an anion;

20 q represents m/p; and,

p represents an integer;

or a pharmaceutically acceptable derivative of a compound of formula (1).

The polymer, P, preferably comprises a carboxyl group-containing polysaccharide.

25 Preferred polysaccharides are selected from the group consisting of carboxyl group-containing celluloses, modified starches, oxidized regenerated cellulose, chitosans, guar gums, glycans, galactans, glucans, xanthan gums, alginic acids, polymannuric acids, hyaluronic acids, polyglycosuronic and polyguluronic acids, mannans, dextrans, cyclodextrins and mixtures thereof, as well as other synthetically carboxylated or
30 naturally occurring carboxylated polysaccharides, which may be linear or branched. P may be a furanosan or pyranosan associated with proteins, lipids, or other molecules, and

may include algal, plant, bacterial and mucopolysaccharides, glycogen, pectin, glycoproteins, and glycolipids.

P may comprise a synthetic polymer. Preferred synthetic polymers include those
 5 obtainable by homo- or co-polymerisation of (meth)acrylic monomers. Preferred monomers are selected from the group consisting of (meth)acrylic acid, methyl (meth)acrylate, ethyl (meth)acrylate, n-propyl (meth)acrylate, isopropyl (meth)acrylate, n-butyl (meth)acrylate, isobutyl (meth)acrylate, tert-butyl (meth)acrylate, n-pentyl (meth)acrylate, n-hexyl (meth)acrylate, cyclohexyl (meth)acrylate, n-heptyl
 10 (meth)acrylate, n-octyl (meth)acrylate, 2-ethylhexyl (meth)acrylate, nonyl (meth)acrylate, decyl (meth)acrylate, dodecyl (meth)acrylate, phenyl (meth)acrylate, toluyl (meth)acrylate, benzyl (meth)acrylate, 2-methoxyethyl (meth)acrylate, 3-methoxybutyl (meth)acrylate, 2-hydroxyethyl (meth)acrylate, 2-hydroxypropyl (meth)acrylate, stearyl (meth)acrylate, glycidyl (meth)acrylate, 2-aminoethyl
 15 (meth)acrylate, (meth)acrylic acid-ethylene oxide adducts, trifluoromethylmethyl (meth)acrylate, 2-trifluoromethylethyl (meth)acrylate, 2-perfluoroethylethyl (meth)acrylate, 2-perfluoroethyl-2-perfluorobutylethyl (meth)acrylate, 2-perfluoroethyl (meth)acrylate, perfluoromethyl (meth)acrylate, diperfluoromethylmethyl (meth)acrylate, 2-perfluoromethyl-2-perfluoroethylmethyl (meth)acrylate, 2-perfluorohexylethyl
 20 (meth)acrylate, 2-perfluorodecylethyl (meth)acrylate, 2-perfluorohexadecylethyl (meth)acrylate and mixtures thereof.

..... Synthetic polymers may be graft or direct polymers or copolymers.

25 Preferably, polymer P is not biodegradable.

Hyaluronic acid, gellan, xanthan, succinoglycan, pectin, oxidized regenerated cellulose, chondroitin sulphate, heparan sulphate, dermatan are preferred examples of carboxylated polysaccharides. Alginic acid and hyaluronic acid are most preferred, particularly
 30 alginic acid.

Preferably, the polymer P comprises $10^{-1} \times 10^7$ monomeric units, more preferably $20^{-1} \times 10^6$, more preferably $30^{-1} \times 10^5$, more preferably $40^{-1} \times 10^4$ most preferably greater than 1000 monomeric units.

5

Preferably, greater than 10% of the monomeric units in the polymer comprise at least one carboxyl group, more preferably, greater than 25%, more preferably greater than 50%, more preferably greater than 70%, more preferably greater than 80%, more preferably greater than 90% of the monomeric units in the polymer comprise at least one carboxyl
10 group.

Preferably, greater than 0.1% of the carboxyl groups in the polymer are modified with group X. More preferably, greater than 1%, more preferably greater than 5%, more preferably greater than 10% of the carboxyl groups in the polymer are modified with
15 group X.

R is preferably selected from the group consisting of C_{1-20} alkanediyl, C_{2-20} alkenediyl, C_{2-20} alkynediyl, C_{3-30} cycloalkanediyl, C_{3-30} cycloalkenediyl, C_{5-30} cycloalkynediyl, , C_{7-30} aralkylenediyl, C_{7-30} alkarylenediyl and C_{5-30} arylenediyl.
20

R is more preferably selected from the group consisting of C_{1-16} alkanediyl, C_{2-16} alkenediyl, C_{2-16} alkynediyl, C_{4-20} cycloalkanediyl, C_{4-20} cycloalkenediyl, C_{5-20} cycloalkynediyl, C_{7-20} aralkylenediyl, C_{7-20} alkarylenediyl and C_{6-20} arylenediyl.

25 R is more preferably selected from the group consisting of straight chain C_{1-16} alkanediyl, C_{2-16} alkenediyl, C_{6-16} aralkylenediyl and C_{6-16} alkarylenediyl.

Most preferably, R is selected from methylene, 1,2-ethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene, 1,8-octylene, 1,10-decylene and 1,12-dodecylene.
30

All groups R may be the same.

R may contain no heteroatoms.

R may comprise hydrocarbon chains that all contain the same number of carbon atoms.

5

Preferably, R comprises a mixture of hydrocarbon chains.

Preferably, R has greater than 2 carbon atoms in the chain, preferably 3 to 10, and more preferably 3, 6, 8 or 10.

10

R^1 is preferably selected from the group consisting of C_{1-30} alkanediyl, C_{2-30} alkenediyl, C_{2-30} alkynediyl, C_{3-35} cycloalkanediyl, C_{3-35} cycloalkenediyl, C_{5-35} cycloalkynediyl, C_{7-35} aralkylenediyl, C_{7-35} alkarylenediyl and C_{5-35} arylenediyl.

15 R^1 is more preferably selected from the group consisting of C_{1-18} alkanediyl, C_{2-18} alkenediyl, C_{2-18} alkynediyl, C_{4-20} cycloalkanediyl, C_{4-20} cycloalkenediyl, C_{5-20} cycloalkynediyl, C_{7-20} aralkylenediyl, C_{7-20} alkarylenediyl and C_{6-20} arylenediyl.

R^1 is more preferably selected from the group consisting of straight chain C_{1-18} alkanediyl, C_{2-18} alkenediyl, C_{6-18} aralkylenediyl and C_{6-18} alkarylenediyl.

20

All groups R^1 may be the same.

Preferably, R^1 may comprise a mixture of hydrocarbon chains. Preferably, at least some of the hydrocarbon chains R^1 in the mixture have 12-18 carbon atoms, preferably 12-16 carbon atoms, more preferably 12 or 16 carbon atoms. In particular, for each compound (1), group X comprising a mixture of R^1 carbon chain lengths of C_{12} to C_{16} inclusive, are preferred.

25

30 R^2 is preferably -H.

Y preferably represents an anion, or plurality of anions, which may be the same or different, that balance the charge of positively charged moiety V. The anion may be singly charged, in which case p in formula (1) is 1, doubly charged, in which case p in formula (1) is 2, and so on.

5

Examples of suitable anions, Y, include, N-hydroxysuccinimidyl, N-hydroxybenzotriazolyl, nitrate, sulfate, bisulfate, phosphate (mono-, bi-, or triphosphate), carbonate, bicarbonate, acetate, tosylates, mesylates, brosylates, and halides including chloride, bromide, and iodide, and mixtures thereof.

10

Preferably, m is an integer of 1, 2, 3, 4, 5 or 6. Preferably, p is an integer of 1, 2, 3, 4, 5 or 6. Preferably, m is 1, 2 or 3, preferably 1 or 2. Preferably p is 1, 2 or 3, preferably 1 or 2.

15 Preferably, the overall charge of the compound of formula (1) is neutral, therefore, for example, when $m = 2$ and $p = 1$, $q = 2$. Alternatively, for example, when $m = 2$ and $p = 2$, $q = 1$. Alternatively, for example, when $m = 1$ and $p = 1$, $q = 1$. Alternatively for example, when $m = 1$ and $p = 2$, $q = \frac{1}{2}$. Alternatively for example, when $m = 3$ and $p = 2$, $q = \frac{3}{2}$. Alternatively for example, when $m = 2$ and $p = 3$, $q = \frac{2}{3}$.

20

A mixture of anions may be employed, having a mixture of charges. Thus, for any particular tri-cationic moiety V ($m = 3$), Y may be, for example, Cl^- and CO_3^{2-} . Thus, the overall negative charge contributed by the anions, Y, for that V moiety is -3. In this case, q is 2, and p is 1 and 2 for Cl^- and CO_3^{2-} respectively.

25

Where there is more than one anion, Y, in a compound of formula (1) and/or where $q = 2$ or more, Y may be the same or different, preferably the same.

R^3 , R^4 and R^5 are preferably independently selected from the group consisting of -H, C_{1-20} alkyl, C_{2-20} alkenyl, C_{2-20} alkynyl, C_{3-30} cycloalkyl, C_{3-30} cycloalkenyl, C_{4-30} cycloalkynyl, C_{7-30} aralkyl, C_{7-30} alkaryl and C_{5-30} aryl.

30

R^3 , R^4 and R^5 are more preferably independently selected from the group consisting of -H, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, C_{3-20} cycloalkyl, C_{3-20} cycloalkenyl, C_{4-20} cycloalkynyl, C_{7-20} aralkyl, C_{7-20} alkaryl and C_{6-20} aryl.

- 5 R^3 , R^4 and R^5 are more preferably independently selected from the group consisting of -H, straight chain C_{1-10} alkyl, C_{2-10} alkenyl and C_{6-12} aryl.

Most preferably, R^3 , R^4 and R^5 are independently selected from the group consisting of -H, methyl, ethyl, propyl, butyl, hexyl, cyclohexyl, octyl, nonyl, dodecyl, eicosyl,
 10 norbornyl and adamantyl, vinyl, propenyl, cyclohexenyl, benzyl, phenylethyl, phenylpropyl, phenyl, tolyl, dimethylphenyl, trimethylphenyl, ethylphenyl, propylphenyl, biphenyl, naphthyl, methylnaphthyl, anthryl, phenanthryl, benzylphenyl, pyrenyl, acenaphthyl, phenalenyl, aceanthrylenyl, tetrahydronaphthyl, indanyl, biphenyl, particularly methyl, ethyl, propyl and isopropyl.

15

In formula (1), P preferably comprises a polysaccharide, comprising a carboxyl group that has been modified by covalent attachment of the X moiety to the polysaccharide through the carboxyl group.

- 20 Preferably, the polysaccharide, P, comprises $10^{-1} \times 10^5$ monosaccharide moieties, more preferably $20^{-1} \times 10^4$, more preferably $30^{-1} \times 10^4$, more preferably $40^{-1} \times 10^4$ most preferably greater than 100 monosaccharide moieties.

The compound of formula (1) may comprise a mixture of carboxylated monosaccharide
 25 or oligosaccharide moieties within the polysaccharide. The compound of formula (1) may comprise non-carboxylated monosaccharide or oligosaccharide moieties within the polysaccharide.

Preferably, greater than 10% of the monosaccharide moieties in the polysaccharide
 30 comprise at least one carboxyl group, more preferably, greater than 25%, more preferably greater than 50%, more preferably greater than 70%, more preferably greater

than 80%, more preferably greater than 90% of the monosaccharide moieties in the polysaccharide comprise at least one carboxyl group.

Preferably, the compound of formula (1) comprises 10-1000000 carboxyl groups,
5 preferably 20-100000, more preferably 25-10000 carboxyl groups.

Preferably, greater than 0.1% of the carboxyl groups in the polysaccharide are modified with group X. More preferably, greater than 1%, more preferably greater than 5%, more preferably greater than 10% of the carboxyl groups in the polymer are modified with
10 group X.

V in formula (1) comprises a positively charged moiety. The positively charged moiety may, for example, be a singly or a doubly charged moiety. In some compounds, V may comprise 3, 4, 5 or 6 positive charges. In a singly charged moiety, m in formula (1)
15 represents 1. In a doubly charged moiety, m represents 2. The singly or doubly charged moiety may, for example, comprise one or two positively charged nitrogen atoms, one or two positively charged phosphorous atoms, one or two positively charged sulfur atoms, or mixtures thereof, preferably nitrogen atoms.

20 In one embodiment, the positively charged moiety comprises a singly charged quaternary ammonium, quaternary phosphonium or sulfonium group, having the formula $^+NR^6_2$ -, $^+PR^7_2$ -, or $^+SR^8$ -, respectively, wherein R^6 , R^7 and R^8 are independently selected from the group consisting of H and monovalent hydrocarbon radicals.

25 R^6 , R^7 and R^8 are preferably independently selected from the group consisting of -H, C_{1-20} alkyl, C_{2-20} alkenyl, C_{2-20} alkynyl, C_{3-30} cycloalkyl, C_{3-30} cycloalkenyl, C_{4-30} cycloalkynyl, C_{7-30} aralkyl, C_{7-30} alkaryl and C_{5-30} aryl.

R^6 , R^7 and R^8 are more preferably independently selected from the group consisting of -
30 H, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, C_{3-20} cycloalkyl, C_{3-20} cycloalkenyl, C_{4-20} cycloalkynyl, C_{7-20} aralkyl, C_{7-20} alkaryl and C_{6-20} aryl.


R^6 , R^7 and R^8 are more preferably independently selected from the group consisting of — H, straight chain C_{1-10} alkyl, C_{2-10} alkenyl and C_{6-12} aryl.

Most preferably, R^6 , R^7 and R^8 are independently selected from the group consisting of
 5 methyl, ethyl, propyl, butyl, hexyl, cyclohexyl, octyl, nonyl, dodecyl, eicosyl, norbornyl
 and adamantyl, vinyl, propenyl, cyclohexenyl, benzyl, phenylethyl, phenylpropyl,
 phenyl, tolyl, dimethylphenyl, trimethylphenyl, ethylphenyl, propylphenyl, biphenyl,
 naphthyl, methylnaphthyl, anthryl, phenanthryl, benzylphenyl, pyrenyl, acenaphthyl,
 phenalenyl, aceanthrylenyl, tetrahydronaphthyl, indanyl, biphenyl, particularly methyl,
 10 ethyl, propyl and isopropyl.

In the quaternary ammonium ions, the two R^6 groups on the N atom may be the same, or different. Preferably, both R^6 groups represent methyl or ethyl.

15 In the quaternary phosphonium ions, the two R^7 groups on the P atom may be the same, or different. Preferably, both R^7 groups represent methyl or ethyl.


In a preferred embodiment, positively charged moiety V comprises two positively charged nitrogen atoms, such as, for example, $-^+NR^6_2-R^9-NR^6_2^+$ or a group (A):



20

wherein a, b and c independently represent 1-10, preferably, 1-5, more preferably 1-3, most preferably 2. Preferably, $a = b = c$. In a particularly preferred embodiment, (A) is 1,4-diazoniabicyclo[2.2.2]octane.


25 In another embodiment, V comprises two positively charged sulfur atoms, such as, for example, $-^+SR^8-R^{10}-SR^{8+}$ or a group (B)



wherein d and e independently represent 1-10, preferably, 1-5, more preferably 1-3, most preferably 2. Preferably, $a = b = c$. In a particularly preferred embodiment, (B) is 1,4-dithioniumcyclohexane.

5

In another embodiment, V comprises two positively charged phosphorus atoms, such as, for example, $\text{—}^+\text{PR}_2\text{—R}^9\text{—PR}_2^+\text{—}$, or a group (C).



wherein a, b and c independently represent 1-10, preferably, 1-5, more preferably 1-3, most preferably 2. Preferably, $a = b = c$. In a particularly preferred embodiment, (C) is 1,4-diphosphoniabicyclo[2.2.2]octane.

In these embodiments, R^6 , R^7 and R^8 are as defined above, and R^9 , R^9 ' and R^{10} are preferably independently selected from the group consisting of C_{1-20} alkanediyl, C_{2-20} alkenediyl, C_{2-20} alkynediyl, C_{3-30} cycloalkanediyl, C_{3-30} cycloalkenediyl, C_{5-30} cycloalkynediyl, C_{7-30} aralkylenediyl, C_{7-30} alkarylenediyl and C_{5-30} arylenediyl.


R^9 , R^9 ' and R^{10} are more preferably independently selected from the group consisting of C_{1-16} alkanediyl, C_{2-16} alkenediyl, C_{2-16} alkynediyl, C_{4-20} cycloalkanediyl, C_{4-20} cycloalkenediyl, C_{5-20} cycloalkynediyl, C_{7-20} aralkylenediyl, C_{7-20} alkarylenediyl and C_{6-20} arylenediyl.

R^9 , $R^{9'}$ and R^{10} are more preferably independently selected from the group consisting of straight chain C_{1-16} alkanediyl, C_{2-16} alkenediyl, C_{6-16} aralkylenediyl and C_{6-16} alkarylenediyl.

- 5 Most preferably, R^9 , $R^{9'}$ and R^{10} are independently selected from methylene, 1,2-ethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene, 1,8-octylene, 1,10-decylene and 1,12-dodecylene.

- 10 When V comprises ${}^+PR_2^7-R^{9'}-PR_2^{7+}$, each R^7 is preferably phenyl and $R^{9'}$ is preferably ethyl, propyl or butyl.

In a particularly preferred embodiment, the compound of formula (1) comprises $P-(R-V^{m+}-R^1-R^2)$ wherein P, R, V, m, R^1 and R^2 are as defined above. Preferably, $P-(R-$



- 15 $V^{m+}-R^1-R^2$ comprises the structure:

wherein P' comprises a polysaccharide;


h represents 1-10;

a, b, and c are as defined above;

- 20 i represents 7-17; and,

j represents $10^{-1} \times 10^7$.

More preferably, $P-(R-V^{m+}-R^1-R^2)$ has the structure:



wherein P' comprises a polysaccharide;

h represents 3-10;

i represents 11, 13 or 15; and,


5 j represents $30-1 \times 10^7$.

P' is preferably an alginate, preferably alginic acid.

j preferably represents $10-1 \times 10^6$, more preferably $20-1 \times 10^5$, more preferably $30-1 \times 10^4$.

In a further aspect of the present invention there is provided a process for the preparation of a compound having formula (1), comprising reacting a compound having the formula (2):

15



wherein:

P is as defined above, with reference to compound (1);

20 n is as defined above, with reference to compound (1);

Z is a cation;

f represents $1/g$; and

g represents 1, 2, 3, 4, 5 or 6;

with a group having the formula (3)

25



wherein X is as defined above, with reference to compound (1); and,

L is a leaving group.

The term "leaving group" generally refers to groups readily displaceable by a nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, 5 nitrate, sulfate, bisulfate, phosphate (mono-, bi-, or triphosphate), carbonate, bicarbonate, acetate, tosylates, mesylates, brosylates, and halides including chloride, bromide, and iodide. Preferably, L is tosylate.

Z may be any cationic group. Z may be an inorganic or organic compound or ion. 10 Preferably, Z is selected from Group I ($g = 1$) and Group II ($g = 2$) metal ions, in particular Li^+ , Na^+ , K^+ , Mg^{2+} and Ca^{2+} , preferably Na^+ .

g preferably represents an integer that balances the charge of negatively charged moiety $[\text{COO}^-]$. The cation may be singly charged, in which case g in formula (2) is 1; or 15 doubly charged, in which case g in formula (2) is 2. Preferably g is 1, 2 or 3, more preferably 1 or 2.

f preferably represents a fraction or integer that balances the charge of negatively charged moiety $[\text{COO}^-]$. The cation, Z, may be singly charged, in which case f in 20 formula (2) is 1; or doubly charged, in which case f in formula (2) is $\frac{1}{2}$. Preferably $f = 1$ and $g = 1$.

For polymers that have a carboxylic acid group, activation of carboxylic acid group preferably takes place prior to reaction with (3). Activation may be accomplished by 25 converting the carboxylic acid group to an active carboxylate anion.

Carboxylic acid groups may be converted to an active carboxylate anion by reacting the carboxylic acid with a reagent in a suitable medium. The reagent may, for example, include a basic compound. Organic or inorganic basic compounds may be used. For 30 example, the Group I and Group II metal hydroxides, carbonates and bicarbonates are preferred, in particular CaCO_3 , NaCO_3 , NaHCO_3 , NaOH and KOH . Bicarbonates and

hydroxides are particularly preferred. NaHCO_3 is most preferred. The activation is preferably carried out in aqueous media.

Suitable media for the activation reaction include water, hydrocarbons, ethers, halogenated hydrocarbons, ketones, alcohols, nitriles, amines, esters, carbonates and mixtures thereof. Particularly preferred solvents include water and/or alcohol(s). The amount of reagent and volume of suitable medium are known to those in the art.

It is not necessary to activate all of the available carboxylic acid sites present on the surface of a compound having formula (2). For example, less than about 10% of the available carboxylic acid groups on a surface may be activated to subsequently provide sufficient antimicrobial activity. Preferably, about 25% of the available carboxylic acid groups may be activated, more preferably about 50%, and most preferably about 75% of the available carboxylic acid groups may be activated.

15

The reaction of (2) with (3) preferably takes place in the presence of a solvent, preferably an organic solvent.

Preferred organic solvents include hydrocarbons, ethers, halogenated hydrocarbons, ketones, alcohols, nitriles, amines, esters, carbonates and mixtures thereof. Particularly preferred solvents are acetonitrile and alcohols.

Alternatively, or in addition to the organic solvent described above, the reaction of (2) with (3) may take place in the presence of water.

25

The reaction of (2) with (3) is preferably carried out at about ambient temperature (25°C).

According to a further aspect of the present invention there is provided a pharmaceutical composition comprising a compound of the present invention in combination with a pharmaceutically acceptable excipient.

30

According to a further aspect of the present invention there is provided a method of preparing a pharmaceutical composition comprising the step of combining a compound of the present invention with a pharmaceutically acceptable excipient.

- 5 The compounds of the present invention are preferably used in the manufacture of antimicrobial materials. The compounds of formula (1) are suitable for manufacturing objects, such as clothing, bandages, sutures, protective gear, containers, and the like.

The present invention provides improved wound dressing materials for mammalian
10 wounds, and especially for human, chronic wounds, such as venous ulcers, decubitis ulcers and diabetic ulcers. Such chronic wounds generally exhibit little or no bleeding or adhesion to other body tissues.

Compositions and materials manufactured from a compound according to the present
15 invention may also comprise one or more structural proteins selected from the group consisting of fibronectin, fibrin, laminin, elastin, collagen and mixtures thereof. Preferably the protein comprises collagen, and more preferably it consists essentially of collagen.

20 Compositions and materials manufactured from a compound according to the present invention may also comprise 0-10% by weight, preferably 0-5% by weight of one or more therapeutic wound healing agents, such as non-steroidal anti-inflammatory drugs (e.g. acetaminophen), steroids, antibiotics (e.g. penicillins or streptomycins); antiseptics (e.g. silver sulfadiazine or chlorhexidine), or growth factors (e.g. fibroblast growth factor
25 or platelet derived growth factor). All of the above percentages are on a dry weight basis.

A wound dressing is preferably in sheet form and comprises an active layer of the compound according to the invention. The active layer would normally be the wound
30 contacting layer in use, but in some embodiments it could be separated from the wound by a liquid-permeable top sheet. Preferably, the area of the active layer is from about 1cm^2 to about 400cm^2 , more preferably from about 4cm^2 to about 100cm^2 .

Preferably, the wound dressing further comprises a backing sheet extending over the active layer opposite to the wound facing side of the active layer. Preferably, the backing sheet is larger than the active layer such that a marginal region of width 1mm to 50 mm, preferably 5mm to 20mm extends around the active layer to form a so-called island dressing. In such cases, the backing sheet is preferably coated with a pressure sensitive medical grade adhesive in at least its marginal region.

Preferably, the backing sheet is substantially liquid-impermeable. The backing sheet is preferably semipermeable. That is to say, the backing sheet is preferably permeable to water vapour, but not permeable to liquid water or wound exudate. Preferably, the backing sheet is also microorganism-impermeable. Suitable continuous conformable backing sheets will preferably have a moisture vapor transmission rate (MVTR) of the backing sheet alone of 300 to 5000 g/m²/24hrs, preferably 500 to 2000 g/m²/24hrs at 37.5 °C at 100% to 10% relative humidity difference. The backing sheet thickness is preferably in the range of 10 to 1000 micrometers, more preferably 100 to 500 micrometers.

The MVTR of the dressing according to the present invention as a whole is lower than that of the backing sheet alone, because the apertured sheet partially obstructs moisture transfer through the dressing. Preferably, the MVTR of the dressing (measured across the island portion of the dressing) is from 20% to 80% of the MVTR of the backing sheet alone, more preferably from 20% to 60% thereof, and most preferably about 40% thereof. It has been found that such moisture vapor transmission rates allow the wound under the dressing to heal under moist conditions without causing the skin surrounding the wound to macerate.

Suitable polymers for forming the backing sheet include polyurethanes and polyalkoxyalkyl acrylates and methacrylates such as those disclosed in GB-A-1280631. An endotoxin and/or exotoxin absorbant material, for example, a charcoal containing material is preferred. Preferably, the backing sheet comprises a continuous layer of a high density blocked polyurethane foam that is predominantly closed-cell. A suitable backing sheet

material is the polyurethane film available under the Registered Trade Mark ESTANE 5714F.

5 The adhesive (where present) layer should be moisture vapor transmitting and/or patterned to allow passage of water vapor therethrough. The adhesive layer is preferably a continuous moisture vapor transmitting, pressure-sensitive adhesive layer of the type conventionally used for island-type wound dressings, for example, a pressure sensitive adhesive based on acrylate ester copolymers, polyvinyl ethyl ether and polyurethane as described for example in GB-A-1280631. The basis weight of the adhesive layer is
10 preferably 20 to 250 g/m², and more preferably 50 to 150 g/m². Polyurethane-based pressure sensitive adhesives are preferred.

Further layers of a multilayer absorbent article may be built up between the active layer and the protective sheet.

15

The dressing may further comprise an absorbent layer between the active layer and the protective sheet, especially if the dressing is for use on exuding wounds. The optional absorbent layer may be any of the layers conventionally used for absorbing wound fluids, serum or blood in the wound healing art, including gauzes, nonwoven fabrics,
20 superabsorbents, hydrogels and mixtures thereof. Preferably, the absorbent layer comprises a layer of absorbent foam, such as an open celled hydrophilic polyurethane foam prepared in accordance with EP-A-0541391, the entire content of which is expressly incorporated herein by reference. In other embodiments, the absorbent layer may be a nonwoven fibrous web, for example a carded web of viscose staple fibers. The
25 basis weight of the absorbent layer may be in the range of 50-500g/m², such as 100-400g/m². The uncompressed thickness of the absorbent layer may be in the range of from 0.5mm to 10mm, such as 1mm to 4mm. The free (uncompressed) liquid absorbency measured for physiological saline may be in the range of 5 to 30 g/g at 25° C.

30

The wound facing surface of the dressing is preferably protected by a removable cover sheet. The cover sheet is normally formed from flexible thermoplastic material.

Suitable materials include polyesters and polyolefins. Preferably, the adhesive- facing surface of the cover sheet is a release surface. For example, the cover sheet may be formed from a non-adherent plastic such as a fluoropolymer, or it may be provided with a release coating such as a silicone or fluoropolymer release coating.

5

Preferably, the wound dressing is sterile and packaged in a microorganism-impermeable container.

The dressings according to the present invention may further comprise other medically acceptable materials, including textile fibers such as nylon or polyester staple fibers, nontextile fibers such as meltblown nylon fibers, and bioresorbable fibers such as polylactide/polyglycolide fibers.

In another aspect, the present invention provides a method of treatment of a chronic wound in a mammal, such as a decubitis ulcer, a venous ulcer or a diabetic ulcer. The method comprises applying a dressing as defined above to the wound.

Preferably, the dressing is applied to the chronic wound for a period of at least 1 hour, more preferably at least 6 hours, and most preferably at least 12 hours. The treatment may be extended for several days or weeks, with dressing changes as appropriate, if necessary for chronic wounds.

The compounds of the present invention may be used in a method of medical treatment, of the human or animal body, by way of therapy.

25

The compounds of the present invention may be used in a method of preparing a medicament, used in the treatment of bacterial infection.

The present invention further provides a method of treating a patient for bacterial infection, comprising administering a therapeutically effective amount of a compound according to the present invention.

30

As used herein, the term "divalent hydrocarbon radicals" refers to any straight chain, branched, cyclic, acyclic, heterocyclic, saturated or unsaturated diradical, which contains a carbon backbone comprising one or more hydrogen atoms, optionally substituted with one or more heteroatoms in or on the carbon backbone. The term "divalent hydrocarbon radical" is intended to encompass the terms "alkanediyl", "alkenediyl", "alkynediyl", "cycloalkanediyl", "cycloalkenediyl", "cycloalkynediyl", "arylenediyl", "aralkylenediyl" and "alkarylenediyl" as defined below.

The term "alkanediyl" refers to a straight or branched saturated divalent hydrocarbon radical having the number of carbon atoms indicated, optionally substituted with one or more heteroatoms in or on the carbon backbone.

The terms "alkenediyl" and "alkynediyl" refer to straight or branched, unsaturated divalent hydrocarbon radicals, optionally substituted with one or more heteroatoms in or on the carbon backbone. An "alkenediyl" is characterized by a carbon-carbon double bond and an "alkynediyl" is characterized by a carbon-carbon triple bond.

The term "cycloalkanediyl" refers to a cyclic saturated divalent hydrocarbon radical having the number of carbon atoms indicated, optionally substituted with one or more heteroatoms in or on the carbon backbone.

The terms "cycloalkenediyl" and "cycloalkynediyl" refer to cyclic unsaturated divalent hydrocarbon radicals, optionally substituted with one or more heteroatoms in or on the carbon backbone. A "cycloalkenediyl" is characterized by a carbon-carbon double bond and a "cycloalkynediyl" is characterized by a carbon-carbon triple bond.

The term "arylenediyl" refers to a divalent unsaturated aromatic carbocyclic radical having one or two rings, optionally substituted with one or more heteroatoms in or on the carbon backbone.

The term "alkarylenediyl" refers to a divalent unsaturated mono- or di-alkyl-substituted aromatic carbocyclic radical having one or two rings, optionally substituted with one or more heteroatoms in or on the carbon backbone. Binding is through the arylene group.

- 5 The term "aralkylenediyl" refers to a divalent unsaturated mono- or di-alkyl-substituted aromatic carbocyclic radical having one or two rings, optionally substituted with one or more heteroatoms in or on the carbon backbone. Binding is through the alkylene group.

- As used herein, the term "monovalent hydrocarbon radicals" refers to any straight chain,
10 branched, cyclic, acyclic, heterocyclic, saturated or unsaturated radical, which contains a carbon backbone comprising one or more hydrogen atoms, optionally substituted with one or more heteroatoms in or on the carbon backbone. The term "monovalent hydrocarbon radical" is intended to encompass the terms "alkyl", "alkenyl", "alkynyl", "cycloalkyl", "cycloalkenyl", "cycloalkynyl", "alkaryl", "aralkyl" and "aryl" as defined
15 below.

- As used herein, the term "alkyl" refers to a straight or branched saturated monovalent hydrocarbon radical, having the number of carbon atoms as indicated, optionally substituted with one or more heteroatoms in or on the carbon backbone.
20

- As used herein, the term "alkenyl" refers to a straight or branched unsaturated monovalent hydrocarbon radical, having the number of carbon atoms as indicated, optionally substituted with one or more heteroatoms in or on the carbon backbone, and the distinguishing feature of a carbon-carbon double bond.
25

- As used herein, the term "alkynyl" refers to a straight or branched unsaturated monovalent hydrocarbon radical, having the number of carbon atoms as indicated, optionally substituted with one or more heteroatoms in or on the carbon backbone, and the distinguishing feature of a carbon-carbon triple bond.
30

As used herein, the term "cycloalkyl" refers to a cyclic saturated monovalent hydrocarbon radical, having the number of carbon atoms as indicated, optionally substituted with one or more heteroatoms in or on the carbon backbone.

- 5 As used herein, the terms "cycloalkenyl" and "cycloalkynyl" refer to cyclic unsaturated monovalent hydrocarbon radicals, optionally substituted with one or more heteroatoms in or on the carbon backbone. A "cycloalkenyl" is characterized by a carbon-carbon double bond and a "cycloalkynyl" is characterized by a carbon-carbon triple bond.
- 10 As used herein, the term "aryl" refers to a monovalent unsaturated aromatic carbocyclic radical having one or two rings, optionally substituted with one or more heteroatoms in or on the carbon backbone, such as phenyl, naphthyl, indanyl or biphenyl, or to a monovalent unsaturated aromatic heterocyclic radical, optionally substituted with one or more heteroatoms in or on the carbon backbone, such as quinolyl, dihydroisoxazolyl,
- 15 furanyl, imidazolyl, pyridyl, phthalimido, thienyl, thiophenyl, pyrrolyl and the like. Exemplary heterocyclic radicals include pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, tetrahydrofuranyl, pyranyl, pyronyl, pyridyl, pyrazinyl, pyridazinyl, piperidyl, piperazinyl, morpholinyl, thionaphthyl, benzofuranyl, isobenzofuryl, indolyl,
- 20 oxyindolyl, isoindolyl, indazolyl, indolinyl, 7-azaindolyl, isoindazolyl, benzopyranyl, coumarinyl, isocoumarinyl, quinolyl, isoquinolyl, naphthridinyl, cinnolinyl, quinazolinyl, pyridopyridyl, benzoxazinyl, quinoxadinyl, chromenyl, chromanyl, isochromanyl and carbolinyl.
- 25 As used herein, the term "alkaryl" refers to an aryl group with an alkyl substituent. Binding is through the aryl group. Such groups have the number of carbon atoms as indicated, and may be substituted with one or more heteroatoms in or on the carbon backbone.
- 30 As used herein, the term "aralkyl" refers to an alkyl group with an aryl substituent, where binding is through the alkyl group. Such groups have the number of carbon atoms as

indicated, and may be substituted with one or more heteroatoms in or on the carbon backbone.

As used herein, the term "substituted" is contemplated to include all permissible
5 substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have
10 hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds.

15 As used herein, the term "heteroatom" includes N, O, S, P, Si and halogen (including F, Cl, Br and I).

By "a pharmaceutically acceptable derivative" is meant any pharmaceutically acceptable salt, ester or salt of such ester or any other compound which, upon administration to a
20 recipient, is capable of providing (directly or indirectly) a compound (1).

Pharmaceutically acceptable salts are generally acid addition salts, which are preferably such of therapeutically acceptable inorganic or organic acids, such as strong mineral acids, for example hydrohalic. Preferred salts include hydrochloric acid, hydrobromic
25 acid, sulfuric acid, phosphoric acid, nitric acid, aliphatic or aromatic carboxylic or sulfonic acids, for example, formic acid, acetic acid, propionic acid, succinic acid, glycollic acid, lactic acid, malic acid, tartaric acid, gluconic acid, citric acid, maleic acid, fumaric acid, pyruvic acid, phenylacetic acid, benzoic acid, 4-aminobenzoic acid, anthranilic acid, 4-hydroxybenzoic acid, salicylic acid, 4-aminosalicylic acid, pamoic
30 acid, nicotinic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, sulfanilic acid, cyclohexylsulfamic acid and ascorbic acid. For compounds having a free carboxy


group, pharmaceutically acceptable salts are also derived from bases, for example, alkali metal salts, such as the sodium salt, or salts derived from pharmaceutically acceptable amines.

- 5 The invention will now be described with reference to the following Examples. It will be appreciated that what follows is by way of example only and that modifications to detail may be made whilst still falling within the scope of the invention.


Activation of Carboxyl Groups:

10


- A preferred reaction sequence is shown below. The reaction sequence begins with the deprotonation of an alginate dressing with an aqueous solution of sodium bicarbonate as illustrated in Scheme 1. Separately, the species to be conjugated with the dressing is prepared. This process involves treatment of 1,4-diazabicyclo[2.2.2]octane with one
15 equivalent of a haloalkane in EtOAc as shown in Scheme 2. Following the isolation of the monoammonium "string," the free amine is quaternized by the reaction of a halo-1-alkanol in CH_3CN as illustrated in Scheme 3. The final step in preparing the unsymmetrical string for conjugation to the sodium alginate dressing involves tosylation of the terminal hydroxyl group as shown in Scheme 4. The conjugation step involves
20 treatment of the sodium alginate dressing with 2 equivalents of the unsymmetrical tosylated string in CH_3CN . Scheme 5 outlines the final reaction in this process.




Scheme 1




Scheme 2



Scheme 3



Scheme 4



Experimental:

Alginate Conjugation:

- 5 An alginate dressing (Nu-DermTM) was treated with aqueous sodium bicarbonate solution to generate the carboxylic acid site in the anionic state. The concentration of the solution should be kept at 0.025 M. At higher concentrations (i.e. 0.05, 0.75, 0.1, 0.5, 1 M) the dressing is dissolved in it. The dressing is stirred in the solution for 4 days.
- 10 The separately prepared agents are constructed in a two step process. The first step involves reaction of dabco (1,4-diazabicyclo[2.2.2]octane) with the appropriate 1-haloalkane in ethyl acetate medium. The yields of these monocationic species are in the range of 85-95% and quickly precipitate out of solution. The haloalkanes used to render the derivatized alginate surfaces antimicrobial are 1-bromohexadecane and 1-
15 bromododecane. A series of other haloalkanes including 1-bromotetradecane, 1-chlorodecane, 1-bromooctane, 1-chlorohexane, etc. have been synthesised to test their antimicrobial activity.

Subsequently, the second step involves addition of the linker for attaching the agent to
20 the alginate surface. For this two equivalents of the halo-1-alkanol are used to insure the quaternization of the free amine. Depending on the monoammonium string used, the second quaternization may or may not need to be heated. Halo-1-alkanols used include 3-chloro-1-propanol, 4-chloro-1-butanol, 6-chloro-1-hexanol, 8-chloro-1-octanol, and
10-chloro-1-decanol. Alternatively, water and/or alcohol(s) may be used as an
25 alternative to the acetonitrile solvent. The yield is between 40-70% depending on the monoammonium string and the haloalkanols used.

Final preparation of the agent for attachment is accomplished by tosylation of the free hydroxyl group. An excess of tosyl chloride is dissolved in aqueous sodium bicarbonate
30 and the agent added. The reaction mixture is stirred at room temperature for two hours. Depending on the type of unsymmetrical dicationic string prepared, purification may be accomplished by washings with EtOAc and water. Some strings require washing with

other solvents; others do not precipitate out of solution. Those that do not precipitate out are evaporated under reduced pressure, followed by washings for purification.

The suitably activated agent is then coupled with the alginate dressing. The string is first
5 dissolved in the acetonitrile. Depending on the string used, heat may be required to dissolve the compound. After all is completely dissolved, the dressing is added to the solution at room temperature and the reaction mixture is stirred at room temperature for 4 days. The dressing is washed with large amounts of water followed by a wash of anhydrous ether to assist in the drying of the surface. The surface is then left to dry
10 under the hood for one day.

The following alginate derivatives have been prepared:

alginate – C3-dab-C16
15 alginate – C3-dab-C12
alginate – C6-dab-C12
alginate – C6-dab-C16
alginate – C8-dab-C16
alginate – C10-dab-C16

20

Antimicrobial Activity:

The materials prepared above have been subjected to surface modification according to the invention demonstrate excellent antimicrobial properties. In this specification,
25 antimicrobial properties refer to the ability to resist growth of single cell organisms, e.g. bacteria, fungi, algae, and yeast, as well as mold.

The bacteria include both gram positive and gram negative bacteria. Some examples of Gram positive bacteria include, for example, *Bacillus cereus*, *Micrococcus luteus*, and
30 *Staphylococcus aureus*. Some examples of Gram negative bacteria include, for example, *Escherichia coli*, *Enterobacter aerogenes*, *Enterobacter cloacae*, *Proteus vulgaris* and

Pseudomonas aeruginosa. Strains of yeast include, for example, *Saccharomyces cerevisiae*, *Candida* and *Aspergillus*.

In order to demonstrate the antimicrobial properties achieved in accordance with the invention, the materials were modified and tested for antimicrobial activity (Table 1).

While the inventors do not wish to be bound by any theory, the antibacterial activity may be understood as occurring in a stepwise manner. The lipophilic chains may be subsumed by the bacterial species to a stage where the cationic portion is brought into intimate contact with the cell surface, and is subsumed sufficiently far that it is not easily expelled. Detergent-like action then results in cell surface disruption initiating cell destruction. A particular advantage of such action is the lack of consumption of the antibacterial agent. The antibacterial agent is not changed in the process and remains attached to the surface. Moreover, the antibacterial activity is non-specific and non-metabolic. Therefore, the danger of encouraging resistant strains of bacteria is reduced.






Summary of results:

Table 1:





Alginates	E. Coli	P. vulgaris	P.aeruginosa	B. cereus	S. aureus
JE121	3.7	3.9	40	12.9	6.8
JE132	0	0	33	0	0
JE91	6.1	6.3	8	14.6	4.8
TA257	0	1.1	0	0	0
TA258	0.4	0	0.4	0	0
TA259	6.7	0	0	0	0
RC29	0		0		0

The values in each of the columns 2-6 of Table 1 indicate the percentage of growth of bacteria relative to blank systems (non-derivatised alginate).

The structures of the derivatised alginates referred to in Table 1 are as follows:



5



It should be understood that in the Examples illustrated above, the alginate comprises a plurality of the $-(R-V^{m+}-R^1-R^2)$ groups.

Excellent results were obtained with TA257, TA258 and TA259. This differed from the
5 other samples in that the conjugated samples were incubated in bicarbonate for 4 days.

WE CLAIM:

1. An antimicrobial polymeric compound having formula (1):



P comprises a polymer linked to X via a carboxyl group;

X comprises a group $-(R-V^{m+}-R^1-R^2)_q(Y^p-)$;

n is an integer of $1-1 \times 10^7$;

- 10 R is independently selected from divalent hydrocarbon radicals;

V comprises a positively charged moiety;

m represents an integer;

R^1 is independently selected from divalent hydrocarbon radicals;

R^2 is independently selected from the group consisting of -H, -SH, -F, -Cl, -Br, -I, -OR³,

- 15 -HN(O)CR⁴, or -O(O)CR⁵, wherein R³, R⁴ and R⁵ are independently selected from the group consisting of -H and monovalent hydrocarbon radicals;

Y represents an anion;

q represents m/p; and,

p represents an integer;

- 20 or a pharmaceutically acceptable derivative of a compound of formula (1).

2. A compound according to claim 1, wherein P is a carboxyl group-containing polysaccharide.

- 25 3. A compound according to claim 2, wherein the polysaccharide is selected from the group consisting of carboxyl group-containing celluloses, modified starches, chitosans, guar gums, glycans, galactans, glucans, xanthan gums, alginic acids, polymannuric acids, hyaluronic acids, polyglycosuronic and polyguluronic acids, mannans, dextrans, cyclodextrins and mixtures thereof, as well as other synthetically
- 30 carboxylated or naturally occurring carboxylated polysaccharides, which may be linear or branched, preferably hyaluronic acid, gellan, xanthan, succinoglycan, pectin,

chondroitine sulphate, heparan sulphate, dermatan, more preferably alginic acid and hyaluronic acid, particularly alginic acid.

4. A compound according to claim 1, wherein the polymer comprises a synthetic
 5 polymer obtainable by homo- or co-polymerisation of a monomer selected from the
 group consisting of (meth)acrylic acid, methyl (meth)acrylate, ethyl (meth)acrylate, n-
 propyl (meth)acrylate, isopropyl (meth)acrylate, n-butyl (meth)acrylate, isobutyl
 (meth)acrylate, tert-butyl (meth)acrylate, n-pentyl (meth)acrylate, n-hexyl
 (meth)acrylate, cyclohexyl (meth)acrylate, n-heptyl (meth)acrylate, n-octyl
 10 (meth)acrylate, 2-ethylhexyl (meth)acrylate, nonyl (meth)acrylate, decyl (meth)acrylate,
 dodecyl (meth)acrylate, phenyl (meth)acrylate, tolyl (meth)acrylate, benzyl
 (meth)acrylate, 2-methoxyethyl (meth)acrylate, 3-methoxybutyl (meth)acrylate, 2-
 hydroxyethyl (meth)acrylate, 2-hydroxypropyl (meth)acrylate, stearyl (meth)acrylate,
 glycidyl (meth)acrylate, 2-aminoethyl (meth)acrylate, (meth)acrylic acid-ethylene oxide
 15 adducts, trifluoromethylmethyl (meth)acrylate, 2-trifluoromethylethyl (meth)acrylate, 2-
 perfluoroethylethyl (meth)acrylate, 2-perfluoroethyl-2-perfluorobutylethyl (meth)acrylate,
 2-perfluoroethyl (meth)acrylate, perfluoromethyl (meth)acrylate,
 diperfluoromethylmethyl (meth)acrylate, 2-perfluoromethyl-2-perfluoroethylmethyl
 (meth)acrylate, 2-perfluorohexylethyl (meth)acrylate, 2-perfluorodecylethyl
 20 (meth)acrylate, 2-perfluorohexadecylethyl (meth)acrylate and mixtures thereof.

5. A compound according to claim 1, wherein the polymer P comprises $10^{-1} \times 10^7$
 monomeric units, more preferably $20^{-1} \times 10^6$, more preferably $30^{-1} \times 10^5$, more
 preferably $40^{-1} \times 10^4$ most preferably greater than 1000 monomeric units.

25

6. A compound according to any preceding claim, wherein R^2 is -H.

7. A compound according to any preceding claim, wherein R is selected from the
 group consisting of C_{1-20} alkanediyl, C_{2-20} alkenediyl, C_{2-20} alkynediyl, C_{3-30}
 30 cycloalkanediyl, C_{3-30} cycloalkenediyl, C_{5-30} cycloalkynediyl, C_{7-30} aralkylenediyl, C_{7-30}
 alkarylenediyl and C_{5-30} arylenediyl, preferably selected from the group consisting of C_{1-}
 16 alkanediyl, C_{2-16} alkenediyl, C_{2-16} alkynediyl, C_{4-20} cycloalkanediyl, C_{4-20}

cycloalkenediyl, C₅₋₂₀ cycloalkynediyl, C₇₋₂₀ aralkylenediyl, C₇₋₂₀ alkarylenediyl and C₆₋₂₀ arylenediyl, more preferably selected from the group consisting of straight chain C₁₋₁₆ alkanediyl, C₂₋₁₆ alkenediyl C₆₋₁₆ aralkylenediyl and C₆₋₁₆ alkarylenediyl, most preferably, R is selected from methylene, 1,2-ethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene, 1,8-octylene, 1,10-decylene and 1,12-dodecylene.

8. A compound according to any preceding claim, wherein substantially all groups R are the same.

10

9. A compound according to any of claims 1 to 7, wherein R represents a mixture of hydrocarbon chains.

10. A compound according to any preceding claim, wherein R¹ is selected from the group consisting of C₁₋₃₀ alkanediyl, C₂₋₃₀ alkenediyl, C₂₋₃₀ alkynediyl, C₃₋₃₅ cycloalkanediyl, C₃₋₃₅ cycloalkenediyl, C₅₋₃₅ cycloalkynediyl, C₇₋₃₅ aralkylenediyl, C₇₋₃₅ alkarylenediyl and C₅₋₃₅ arylenediyl, preferably selected from the group consisting of C₁₋₁₈ alkanediyl, C₂₋₁₈ alkenediyl, C₂₋₁₈ alkynediyl, C₄₋₂₀ cycloalkanediyl, C₄₋₂₀ cycloalkenediyl, C₅₋₂₀ cycloalkynediyl, C₇₋₂₀ aralkylenediyl, C₇₋₂₀ alkarylenediyl and C₆₋₂₀ arylenediyl, more preferably selected from the group consisting of straight chain C₁₋₁₅ alkanediyl, C₂₋₁₅ alkenediyl, C₆₋₁₅ aralkylenediyl and C₆₋₁₅ alkarylenediyl, most preferably, R¹ is selected from 1,6-hexylene, 1,8-octylene, 1,10-decylene and 1,12-dodecylene.

11. A compound according to any preceding claim, wherein R¹ comprises a mixture of hydrocarbon chains.

12. A compound according to claim 11, wherein at least some of the hydrocarbon chains R¹ in the mixture have 12-18 carbon atoms, preferably 12-16 carbon atoms, more preferably 12 or 16 carbon atoms.

13. A compound according to claim 11, wherein R^1 has greater than 10 carbon atoms in the chain, preferably R^1 comprises 12 or 16 carbon atoms.
14. A compound according to any preceding claim, wherein m is 1, 2, 3, 4, 5 or 6, preferably 1, 2 or 3.
15. A compound according to claim 14, wherein m 1 or 2.
16. A compound according to any of claims 1 to 13, wherein p is 1, 2, 3, 4, 5 or 6, preferably 1, 2 or 3.
17. A compound according to any preceding claim, wherein Y represents one or more anions that balance the charge of positively charged moiety V.
18. A compound according to any preceding claim, wherein Y is selected from the group consisting of N-hydroxysuccinimidyl, N-hydroxybenzotriazolyl, nitrate, sulfate, bisulfate, phosphate (mono-, bi-, or triphosphate), carbonate, bicarbonate, acetate, tosylates, mesylates, brosylates, and halides including chloride, bromide, and iodide and mixtures thereof.
19. A compound according to any preceding claim, wherein R^3 , R^4 and R^5 are independently selected from the group consisting of -H, C_{1-20} alkyl, C_{2-20} alkenyl, C_{2-20} alkynyl, C_{3-30} cycloalkyl, C_{3-30} cycloalkenyl, C_{4-30} cycloalkynyl, C_{7-30} aralkyl, C_{7-30} alkaryl and C_{5-30} aryl, preferably R^3 , R^4 and R^5 are independently selected from the group consisting of -H, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, C_{3-20} cycloalkyl, C_{3-20} cycloalkenyl, C_{4-20} cycloalkynyl, C_{7-20} aralkyl, C_{7-20} alkaryl and C_{6-20} aryl, more preferably R^3 , R^4 and R^5 are independently selected from the group consisting of -H, straight chain C_{1-10} alkyl, C_{2-10} alkenyl and C_{6-12} aryl, most preferably, R^3 , R^4 and R^5 are independently selected from the group consisting of H, methyl, ethyl, propyl, butyl, hexyl, cyclohexyl, octyl, nonyl, dodecyl, eicosyl, norbornyl, adamantyl, vinyl, propenyl, cyclohexenyl, benzyl, phenylethyl, phenylpropyl, phenyl, tolyl, dimethylphenyl, trimethylphenyl, ethylphenyl, propylphenyl, biphenyl, naphthyl, methylnaphthyl, anthryl,

phenanthryl, benzylphenyl, pyrenyl, acenaphthyl, phenalenyl, aceanthrylenyl, tetrahydronaphthyl, indanyl, biphenyl, particularly methyl, ethyl, propyl and isopropyl.


20. A compound according to any preceding claim, wherein the polysaccharide, P,
5 comprises $10^{-1} \times 10^5$ monosaccharide moieties, more preferably $20^{-1} \times 10^4$, more preferably $30^{-1} \times 10^4$, more preferably $40^{-1} \times 10^4$ most preferably greater than 100 monosaccharide moieties.

21. A compound according to any preceding claim, wherein V comprises a positively
10 charged moiety comprising one or two positively charged nitrogen atoms, one or two positively charged phosphorous atoms, one or two positively charged sulfur atoms, or mixtures thereof, preferably nitrogen atoms.

22. A compound according to any preceding claim, wherein V comprises a singly
15 charged quaternary ammonium, quaternary phosphonium or sulfonium group, having the formula $^+NR^6_2-$, $^+PR^7_2-$, or $^+SR^8-$, respectively, wherein R^6 , R^7 and R^8 are independently selected from the group consisting of H and monovalent hydrocarbon radicals.

23. A compound according to claim 22, wherein R^6 , R^7 and R^8 are independently
20 selected from the group consisting of -H, C_{1-20} alkyl, C_{2-20} alkenyl, C_{2-20} alkynyl, C_{3-30} cycloalkyl, C_{3-30} cycloalkenyl, C_{4-30} cycloalkynyl, C_{7-30} aralkyl, C_{7-30} alkaryl and C_{5-30} aryl, preferably R^6 , R^7 and R^8 are independently selected from the group consisting of -H, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, C_{3-20} cycloalkyl, C_{3-20} cycloalkenyl, C_{4-20} cycloalkynyl, C_{7-20} aralkyl, C_{7-20} alkaryl and C_{6-20} aryl, more preferably R^6 , R^7 and R^8 are
25 independently selected from the group consisting of -H, straight chain C_{1-10} alkyl, C_{2-10} alkenyl and C_{6-12} aryl, most preferably, R^6 , R^7 and R^8 are independently selected from the group consisting of methyl, ethyl, propyl, butyl, hexyl, cyclohexyl, octyl, nonyl, dodecyl, eicosyl, norbornyl and adamantyl, vinyl, propenyl, cyclohexenyl, benzyl, phenylethyl, phenylpropyl, phenyl, tolyl, dimethylphenyl, trimethylphenyl, ethylphenyl,
30 propylphenyl, biphenyl, naphthyl, methylnaphthyl, anthryl, phenanthryl, benzylphenyl, pyrenyl, acenaphthyl, phenalenyl, aceanthrylenyl, tetrahydronaphthyl, indanyl, biphenylyl, particularly methyl, ethyl, propyl and isopropyl.

24. A compound according to claim 22 or claim 23, wherein V comprises two positively charged nitrogen atoms, preferably $^+NR^6_2-R^9-NR^6_2^+$ or a group (A):




5 wherein a, b and c independently represent 1-10, preferably, 1-5, more preferably 1-3, most preferably 2, and wherein R^9 is selected from the group consisting of C_{1-20} alkanediyl, C_{2-20} alkenediyl, C_{2-20} alkynediyl, C_{3-30} cycloalkanediyl, C_{3-30} cycloalkenediyl, C_{5-30} cycloalkynediyl, C_{7-30} aralkylenediyl, C_{7-30} alkarylenediyl and C_{5-30} arylenediyl, 10 preferably R^9 is selected from the group consisting of C_{1-16} alkanediyl, C_{2-16} alkenediyl, C_{2-16} alkynediyl, C_{4-20} cycloalkanediyl, C_{4-20} cycloalkenediyl, C_{5-20} cycloalkynediyl, C_{7-20} aralkylenediyl, C_{7-20} alkarylenediyl and C_{6-20} arylenediyl, more preferably R^9 is selected from the group consisting of straight chain C_{1-16} alkanediyl, C_{2-16} alkenediyl, C_{6-16} aralkylenediyl and C_{6-16} alkarylenediyl, most preferably, R^9 is selected from methylene, 15 1,2-ethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene, 1,8-octylene, 1,10-decylene and 1,12-dodecylene.

25. A compound according to claim 24, wherein (A) is 1,4-diazoniabicyclo[2.2.2]octane.

20

26. A compound according to claim 22 or claim 23, wherein V comprises two positively charged sulfur atoms, preferably $^+SR^8-R^{10}-SR^{8+}$ or a group (B)




wherein d and e independently represent 1-10, preferably, 1-5, more preferably 1-3, most preferably 2, and wherein R^{10} is selected from the group consisting of C_{1-20} alkanediyl, C_{2-20} alkenediyl, C_{2-20} alkynediyl, C_{3-30} cycloalkanediyl, C_{3-30} cycloalkenediyl, C_{5-30} cycloalkynediyl, C_{7-30} aralkylenediyl, C_{7-30} alkarylenediyl and C_{5-30} arylenediyl, preferably R^{10} is selected from the group consisting of C_{1-16} alkanediyl, C_{2-16} alkenediyl, C_{2-16} alkynediyl, C_{4-20} cycloalkanediyl, C_{4-20} cycloalkenediyl, C_{5-20} cycloalkynediyl, C_{7-20} aralkylenediyl, C_{7-20} alkarylenediyl and C_{6-20} arylenediyl, more preferably R^{10} is selected from the group consisting of straight chain C_{1-16} alkanediyl, C_{2-16} alkenediyl, C_{6-16} aralkylenediyl and C_{6-16} alkarylenediyl, most preferably, R^{10} is selected from methylene, 1,2-ethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene, 1,8-octylene, 1,10-decylene and 1,12-dodecylene.

27. A compound according to claim 26, wherein (B) is 1,4-dithioniumcyclohexane.

15

28. A compound according to claim 22 or claim 23, wherein V comprises two positively charged phosphorus atoms, preferably $^+\text{PR}_2^7\text{---R}^9\text{---PR}_2^7+$ or a group (C)




wherein a, b and c independently represent 1-10, preferably, 1-5, more preferably 1-3, most preferably 2, and wherein R^9 is selected from the group consisting of C_{1-20} alkanediyl, C_{2-20} alkenediyl, C_{2-20} alkynediyl, C_{3-30} cycloalkanediyl, C_{3-30} cycloalkenediyl, C_{5-30} cycloalkynediyl, C_{7-30} aralkylenediyl, C_{7-30} alkarylenediyl and C_{5-30} arylenediyl, preferably R^9 is selected from the group consisting of C_{1-16} alkanediyl, C_{2-16} alkenediyl, C_{2-16} alkynediyl, C_{4-20} cycloalkanediyl, C_{4-20} cycloalkenediyl, C_{5-20} cycloalkynediyl, C_{7-20}

aralkylenediyl, C₇₋₂₀ alkarylenediyl and C₆₋₂₀ arylenediyl, more preferably R^{9'} is selected from the group consisting of straight chain C₁₋₁₆ alkanediyl, C₂₋₁₆ alkenediyl, C₆₋₁₆ aralkylenediyl and C₆₋₁₆ alkarylenediyl, most preferably, R^{9'} is selected from methylene, 1,2-ethylene, 1,2-propylene, 1,3-propylene, 1,2-butylene, 1,3-butylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene, 1,8-octylene, 1,10-decylene and 1,12-dodecylene.

29. A compound according to claim 28, wherein (C) is 1,4-diphosphoniabicyclo[2.2.2]octane.

10 30. A process for the preparation of a compound having formula (1), comprising reacting a compound having the formula (2):



15

wherein:

P is as defined in any preceding claim;

n is as defined in any preceding claim;

Z is a cation;

20 f represents 1/g; and

g represents 1, 2, 3, 4, 5 or 6;

with a group having the formula (3)



25

wherein X is as defined in any preceding claim; and,

L is a leaving group.

31. A process according to claim 30 wherein L is selected from the group consisting
30 of N-hydroxysuccinimide, N-hydroxybenzotriazole, nitrate, sulfate, bisulfate, phosphate (mono-, bi-, or triphosphate), carbonate, bicarbonate, acetate, tosylates, mesylates, brosylates, and halides including chloride, bromide, and iodide, preferably tosylate.

32. Use of a compound according to any of claims 1 to 29, in the manufacture of antimicrobial materials.
- 5 33. A wound dressing comprising a compound according to any of claims 1 to 29.
34. A wound dressing according to claim 33, for mammalian wounds, and especially for human, chronic wounds, such as venous ulcers, decubitis ulcers and diabetic ulcers.
- 10 35. An antimicrobial surface comprising a compound according to any of claims 1 to 29.
36. A pharmaceutical composition comprising a compound according to any of claims 1 to 29, in combination with a pharmaceutically acceptable excipient.
- 15 37. A compound according to any of claims 1 to 29, for use in a method of medical treatment, of the human or animal body, by way of therapy.
38. Use of a compound according to any of claims 1 to 29, in a method of
- 20 manufacture of a medicament, for the treatment of microbial, preferably bacterial infection.
39. A method of treating a patient for a microbial infection, preferably a bacterial infection, comprising administering a therapeutically effective amount of a compound
- 25 according to any of claims 1 to 29.

ABSTRACT

The present invention is concerned with providing antimicrobial compounds and processes for the production thereof. More particularly, the present invention provides antimicrobial
5 polymeric materials comprising a polymer linked to a positively charged moiety via a carboxyl group. The present invention also provides processes for the production of such antimicrobial compounds and uses therefor.

PCT/GB2004/003465

